- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02916017
HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
HUMIRA® Special Investigation (Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis)
Studieoversikt
Status
Forhold
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Kagoshima, Japan, 890-8520
- Kagoshima Uni Med and Dental /ID# 164150
-
Kakogawa, Japan, 489-0065
- Kakogawa Central City Hospital /ID# 167706
-
Miyakonojo, Japan, 885-0051
- Miyata Ophthalmic Hospital /ID# 167707
-
Nishinomiya-shi, Japan, 663-8501
- Duplicate_The Hospital of Hyogo College /ID# 166913
-
Omihachiman, Japan, 523-0082
- Omihachiman Community Med Ctr /ID# 164978
-
Osaka, Japan, 572-0854
- Osaka Hospital /ID# 164151
-
Osaka-shi, Japan
- Yodogawa Christian Hospital /ID# 161741
-
Seto, Japan, 489-8642
- Tosei General Hospital /ID# 167708
-
Tokorozawa, Japan, 359-0042
- Natl Defense Med College Hosp /ID# 162946
-
Tokyo, Japan, 108-6303
- Abbott Japan /ID# 147893
-
Tokyo, Japan, 162-8543
- Tokyo Shinjuku Medical Center /ID# 166934
-
Tottori, Japan, 680-8501
- Tottori Municipal Hospital /ID# 159431
-
-
Chiba
-
Urayasu-shi, Chiba, Japan, 279-0021
- Juntendo University Urayasu Hospital /ID# 168358
-
-
Ehime
-
Matsuyama-shi, Ehime, Japan, 790-0826
- Matsuyama Red Cross Hospital /ID# 164149
-
-
Fukuoka
-
Fukuoka-shi, Fukuoka, Japan, 812-8582
- Kyushu University Hospital /ID# 163042
-
Fukuoka-shi, Fukuoka, Japan, 814-0180
- Fukuoka University Hospital /ID# 163043
-
Kurume-shi, Fukuoka, Japan, 830-0011
- Kurume University Hospital /ID# 162945
-
-
Gunma
-
Maebashi-shi, Gunma, Japan, 371-8511
- Gunma University Hospital /ID# 166916
-
-
Hiroshima
-
Hiroshima-shi, Hiroshima, Japan, 734-8551
- Hiroshima University Hospital /ID# 166915
-
-
Hokkaido
-
Sapporo-shi, Hokkaido, Japan, 060-8648
- Hokkaido University Hospital /ID# 163041
-
-
Hyogo
-
Kobe-shi, Hyogo, Japan, 650-0017
- Kobe University Hospital /ID# 165250
-
-
Ishikawa
-
Kanazawa-shi, Ishikawa, Japan, 920-8641
- Duplicate_Kanazawa University Hospital /ID# 166914
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 240-8555
- Yokohama Municipal Citizen's Hospital /ID# 161742
-
-
Kochi
-
Nankoku-shi, Kochi, Japan, 783-8505
- Kochi Medical School Hospital /ID# 164144
-
-
Nagano
-
Matsumoto-shi, Nagano, Japan, 390-8621
- Shinshu University Hospital /ID# 164153
-
-
Niigata
-
Niigata-shi, Niigata, Japan, 951-8520
- Niigata University Medical & Dental Hospital /ID# 169563
-
-
Osaka
-
Suita-shi, Osaka, Japan, 565-0871
- Osaka University Hospital /ID# 164147
-
-
Saitama
-
Iruma-gun, Saitama, Japan, 350-0451
- Saitama Medical University Hospital /ID# 162944
-
-
Tochigi
-
Shimotsuga-gun, Tochigi, Japan, 321-0293
- Dokkyo Medical University Hospital /ID# 164154
-
-
Tokushima
-
Tokushima-shi, Tokushima, Japan, 770-8503
- Tokushima University Hospital /ID# 164145
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 113-8431
- Juntendo University Hospital /ID# 169564
-
Bunkyo-ku, Tokyo, Japan, 113-8519
- Tokyo Medical And Dental University, Medical Hospital /ID# 165251
-
Bunkyo-ku, Tokyo, Japan, 113-8603
- Nippon Medical School Hospital /ID# 166938
-
Bunkyo-ku, Tokyo, Japan, 113-8655
- The University of Tokyo Hospital /ID# 162943
-
Minato-ku, Tokyo, Japan, 105-8471
- The Jikei University Hospital /ID# 164152
-
Shinjuku-ku, Tokyo, Japan, 160-0023
- Tokyo Medical University Hospital /ID# 164146
-
Shinjuku-ku, Tokyo, Japan, 162-8655
- Center Hospital of the National Center for Global Health and Medicine /ID# 164148
-
Shinjuku-ku, Tokyo, Japan, 162-8666
- Tokyo Women's Medical University Hospital /ID# 165248
-
-
Yamaguchi
-
Ube-shi, Yamaguchi, Japan, 755-8505
- Yamaguchi University Hospital /ID# 165249
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Exclusion Criteria:
- Participants previously treated with adalimumab
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Kohort
- Tidsperspektiver: Potensielle
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Participants receiving adalimumab
Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Incidence of adverse drug reactions (ADR)
Tidsramme: Up to Week 52
|
ADR is the causal relationship between adalimumab and adverse events.
|
Up to Week 52
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in Visual Functioning Questionnaire (VFQ)-25 score
Tidsramme: From Week 0 (baseline) to Week 52
|
The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning.
The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question.
The overall composite score ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.
|
From Week 0 (baseline) to Week 52
|
Change in Visual acuity in each eye
Tidsramme: From Week 0 (baseline) to Week 52
|
Visual acuity change is assessed.
|
From Week 0 (baseline) to Week 52
|
Change in Anterior Chamber (AC) cell grade (standardization of uveitis nomenclature (SUN) criteria) in each eye
Tidsramme: From Week 0 (baseline) to Week 52
|
Slit lamp examinations will be conducted at each visit to assess AC cell count. The number of AC cells observed within a 1 mm × 1 mm slit beam will be used to determine the grade according to the Standardization of Uveitis Nomenclature (SUN) criteria: Grade 0 = < 1 cell Grade 0.5+ = 1 - 5 cells Grade 1+ = 6 - 15 cells Grade 2+ = 16 - 25 cells Grade 3+ = 26 - 50 cells Grade 4+ = > 50 cells. |
From Week 0 (baseline) to Week 52
|
Percentage of Overall improvement
Tidsramme: Up to Week 52
|
This is assessed by physicians.
|
Up to Week 52
|
Change in retinal lesions in each eye
Tidsramme: From Week 0 (baseline) to Week 52
|
The change in retinal lesion are assessed.
|
From Week 0 (baseline) to Week 52
|
Change in central retinal thickness in each eye
Tidsramme: From Week 0 (baseline) to Week 52
|
This is assessed by Optical Coherence Tomography (OCT)
|
From Week 0 (baseline) to Week 52
|
Change in Vitreous Haze grade in each eye
Tidsramme: From Week 0 (baseline) to Week 52
|
Vitreous haze will be measured using dilated indirect ophthalmoscopy (DIO) and assessed by the Investigator according to National Eye Institute (NEI)/ SUN criteria: Grade 0: No evident vitreous haze; Grade 0.5+: Slight blurring of the optic disc margin because of the haze; normal striations and reflex of the nerve fiber layer cannot be visualized; Grade 1+: Permits a better definition of both the optic nerve head and the retinal vessels (compared to higher grades); Grade 2+: Permits better visualization of the retinal vessels (compared to higher grades); Grade 3+: Permits the observer to see the optic nerve head, but the borders are quite blurry; Grade 4+: Optic nerve head is obscured. |
From Week 0 (baseline) to Week 52
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- P15-665
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .